MNPR
Monopar TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
MNPR vs peer average
60/100
MNPR vs. peer average (C vs. D)
Grade spread
A 1 · C 3 · D 4 · F 2
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
CAPR is the first available peer comparator.
Similar-sized clinical-stage biopharma, but its indication and regulatory path differ; a loose financing and risk-appetite comparison, not a Wilson disease valuation peer.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
MNPR
Monopar Therapeutics
CAPR
Capricor Therapeutics
Grade
C
F
Momentum
11
4
Value
41
41
Sentiment
75
26
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Defensive
Grade position vs CAPR
MNPR / CAPR
Grade Position
In line
MNPR vs. peer average (C vs. D)
60/100
Momentum
11
MNPRValue
41
MNPRSentiment
75
MNPRRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs MNPR
CAPR is the first peer returned for this comparison set.